These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 16707008)

  • 41. Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.
    Fanis P; Skordis N; Frangos S; Christopoulos G; Spanou-Aristidou E; Andreou E; Manoli P; Mavrommatis M; Nicolaou S; Kleanthous M; Cariolou MA; Christophidou-Anastasiadou V; Tanteles GA; Phylactou LA; Neocleous V
    J Endocrinol Invest; 2018 Oct; 41(10):1149-1157. PubMed ID: 29396759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
    Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.
    Reagh J; Bullock M; Andrici J; Turchini J; Sioson L; Clarkson A; Watson N; Sheen A; Lim G; Delbridge L; Sidhu S; Sywak M; Aniss A; Shepherd P; Ng D; Oei P; Field M; Learoyd D; Robinson BG; Clifton-Bligh RJ; Gill AJ
    Am J Surg Pathol; 2017 Jan; 41(1):75-81. PubMed ID: 27635947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
    Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
    Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.
    Gallel P; Pallares J; Dolcet X; Llobet D; Eritja N; Santacana M; Yeramian A; Palomar-Asenjo V; Lagarda H; Mauricio D; Encinas M; Matias-Guiu X
    Hum Pathol; 2008 Jul; 39(7):994-1001. PubMed ID: 18508109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study.
    Erdogan MF; Gürsoy A; Ozgen G; Cakir M; Bayram F; Ersoy R; Algün E; Cetinarslan B; Cömlekçi A; Kadioglu P; Balci MK; Yetkin I; Kabalak T; Erdogan G
    J Endocrinol Invest; 2005 Oct; 28(9):806-9. PubMed ID: 16370559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A.
    Bae SJ; Kim DJ; Kim JY; Park SY; Choi SH; Song YD; Ki CS; Chung JH
    Thyroid; 2006 Jun; 16(6):609-14. PubMed ID: 16839264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
    Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.
    Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW
    Endocr Pathol; 2016 Dec; 27(4):359-362. PubMed ID: 27379493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.
    Thosani S; Ayala-Ramirez M; Palmer L; Hu MI; Rich T; Gagel RF; Cote G; Waguespack SG; Habra MA; Jimenez C
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1813-9. PubMed ID: 24030942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2.
    Wagner SM; Zhu S; Nicolescu AC; Mulligan LM
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):77-84. PubMed ID: 22584710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases.
    Hofstra RM; Stelwagen T; Stulp RP; de Jong D; Hulsbeek M; Kamsteeg EJ; van den Berg A; Landsvater RM; Vermey A; Molenaar WM; Lips CJ; Buys CH
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2881-4. PubMed ID: 8768845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
    Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid
    Stanescu LS; Ghemigian A; Ciobica ML; Nistor C; Ciuche A; Radu AM; Sandru F; Carsote M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.
    Erlic Z; Hoffmann MM; Sullivan M; Franke G; Peczkowska M; Harsch I; Schott M; Gabbert HE; Valimäki M; Preuss SF; Hasse-Lazar K; Waligorski D; Robledo M; Januszewicz A; Eng C; Neumann HP
    J Clin Endocrinol Metab; 2010 Jan; 95(1):308-13. PubMed ID: 19906784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.
    Qi XP; Zhao JQ; Fang XD; Lian BJ; Li F; Wang HH; Cao ZL; Zheng WH; Cao J; Chen Y
    BMC Cancer; 2021 Apr; 21(1):369. PubMed ID: 33827484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of Newly Identified and Rare Synonymous Genetic Variants in the RET Gene in Patients with Medullary Thyroid Carcinoma in Polish Population.
    Sromek M; Czetwertyńska M; Tarasińska M; Janiec-Jankowska A; Zub R; Ćwikła M; Nowakowska D; Chechlińska M
    Endocr Pathol; 2017 Sep; 28(3):198-206. PubMed ID: 28647780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.